Wu et al. found that CtBP1 may enhance DDP resistance in gastric cancer cells by activating RAD51 expression, suggesting that CtBP1 knockdown could provide a novel therapeutic approach for the clinical treatment of gastric cancer patients [71]. The gene discussed is RAD51; the disease is gastric cancer.